Nordic Life Science
Pharma
Latest Pharma News
RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute (BII) to develop treatments of degenerative eye disorders. The funding will be used to prepare its lead drug RP001 for a clinical
AstraZeneca and Merck & Co have announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Priority Review for the use of
The company announces that the FDA has accepted its sevuparin IND for the treatment of SCD. “The FDA’s decision to accept the IND application for the development of sevuparin in
The two companies can once again expand the Clinical Trials section of the U.S. label of their antidepressant Trintellix (vortioxetine) as the U.S. Food and Drug Administration (FDA) has approved
Recipharm announces that it will continue the manufacturing operations at its facility in Höganäs, Sweden, operations that earlier were set towards being discontinued. In 2017, Recipharm announced the intention to
Nordic Nanovector has announces that Betalutin (177Lu-satetraxetan-lilotomab) has been granted a Promising Innovative Medicine (PIM) designation by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of
Clinical trials
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of
The company announces that the dosing of patients in its first trial PPCT01, studying the safety and tolerability of XEN-D0501
Swedish ExpreS2ion Biotech Holding AB announces that The Jenner Institute of the University of Oxford have presented positive results from
The first patient has been dosed in a Phase 2 study evaluating the company’s cancer immunotherapy, BN-Brachyury, and radiation in
The company announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin (177Lu-satetraxetan-lilotomab) in combination with
The new trial evaluates the combination therapy of CV301 and durvalumab in metastatic colorectal and pancreatic cancers. The first patient
The company has announced that DAYBREAKi, the first phase III study for Lu AF35700, an investigational, novel, once-daily, oral antipsychotic drug
The company has announced results from its phase 3a trial with oral semaglutide for the treatment of adults with type
The company has presented results from its HARMONIZE Global Phase III trial, which investigated the safety and efficacy of Lokelma (sodium zirconium
The two companies have completed the phase III clinical trial (ARAMIS) of darolutamide, the novel oral androgen receptor antagonist for
Nordic Nanovector announces that the first clinical site in the United States (in Long Beach, CA) for the pivotal PARADIGME
AstraZeneca and Merck & Co. have announced detailed results from the Phase III SOLO-1 trial testing Lynparza (olaparib) tablets as
The company and its collaborators have presented interim clinical and biomarker data from BerGenBio’s Phase II clinical programme with bemcentinib
Cantargia has presented interim results from its clinical Phase I/II trial CANFOUR of lead candidate CAN04 (nidanilimab). Data from 16
Swedish Orphan Biovitrum AB (Sobi) releases the primary efficacy results from the phase 2 study with anakinra in patients with
In an in-vivo study involving 16 New Zeeland White rabbits Xlucane (ranibizumab (Lucentis) biosimilar) demonstrated equivalent tolerability and pharmacokinetic profile
Pharma articles
Immunotherapy is the 2016 Clinical Cancer Advance of the Year and a promising new strategy for treating cancer. But how far have we come? The American Society of Clinical Oncology
The high cost and uncertain outcomes of developing new drugs has taken a toll on research over the past several years. Few companies can take the hit of investing hundreds
Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to
The rapid development within nanotechnology drug delivery is creating new possibilities to treat common diseases and improving pharmaceuticals. Safety aspects and competitionwith established treatments are however some of the obstacles
Hans Lennernäs, professor in biopharmaceutics at Uppsala University, has extensive experience in developing drug delivery methods. NLS asked him about his research and ongoing activities in the field. He spoke
Much effort is being made to develop new medicines for diabetes and recent findings indicate the potential for new and improved pharmaceuticals. Diabetes is one of the largest global diseases
Profiles in Pharma
Ironically, there is less serendipity in the success Saeid Esmaeilzadeh and Ashkan Pouya have achieved as business-makers than there is
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief
After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development
Sirpa Jalkanen is a professor in the Academy of Finland, board member of Orion, and cofounder with her husband, Markku
Academia and business don’t always mix, but Agnete B. Fredriksen of Norway has found the formula. While doing research for
Logistics
With a deadline looming to meet a new EU Falsification Medicines Directive (FMD) by 2019, there is no shortage of challenges for packaging experts. Besides satisfying EU requirements, drug manufacturers
Packaging is an often overlooked element of the life science supply chain but the industry needs to step up quality and foster innovation in order to keep up with developments